NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Closes $9M Registered Direct Offering
Clinical stage pharmaceutical company Moleculin Biotech (NASDAQ: MBRX) has closed its offering of 4.29 million registered shares of common stock at a purchase price of $2.10 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, the investor will receive an unregistered warrant to purchase 0.5 of a share of common stock. The warrants are exercisable six months from the date of issuance at a price of $2.80 per share and will expire five years from the initial exercise date. Moleculin intends to use the gross proceeds from the offering, which total approximately…







